FiercePharmaOriginal article
{"a":[{"_":"It's BMS vs. Celgene investors once more after US appeals court revives lawsuit","$":{"href":"/pharma/its-bms-vs-celgene-investors-again-after-us-appeals-court-ruling","hreflang":"en"}}]}
RegulatoryBreyanziNegative
AI Analysis
Summary
A U.S. appeals court has revived a shareholder lawsuit against Bristol Myers Squibb alleging the company deliberately delayed approval of blood cancer drug Breyanzi to avoid paying a $6 billion+ contingent value right to Celgene investors.
Outcome Details
Appeals court revived shareholder lawsuit alleging deliberate delay in drug approval to avoid contingent value right payment
Importance:6/10
Sentiment:
-0.80
litigationshareholder lawsuitcontingent value rightdrug approvalacquisition
Read the original article
Published by FiercePharma on August 14, 2026 11:01 AM